Your browser doesn't support javascript.
loading
The Bergen 4-day treatment for social anxiety disorder: a pilot study.
Hansen, Bjarne; Eide, Thorstein Olsen; Reiråskag, Marie Aaslie; Tjelle, Kristian August; Solem, Stian; Hagen, Kristen.
Afiliación
  • Hansen B; Bergen Center for Brain Plasticity, Haukeland University Hospital, Bergen, Norway.
  • Eide TO; Center for Crisis Psychology, Faculty of Psychology, University of Bergen, Bergen, Norway.
  • Reiråskag MA; Center for Crisis Psychology, Faculty of Psychology, University of Bergen, Bergen, Norway.
  • Tjelle KA; Department of Psychiatry, Molde Hospital, Møre Og Romsdal Hospital Trust, Molde, Norway.
  • Solem S; Department of Health and Nursing Sciences, University of Agder, Kristiansand, Norway.
  • Hagen K; Department of Psychiatry, Molde Hospital, Møre Og Romsdal Hospital Trust, Molde, Norway.
BMC Psychiatry ; 24(1): 145, 2024 Feb 21.
Article en En | MEDLINE | ID: mdl-38383324
ABSTRACT

BACKGROUND:

Few studies have examined the use of concentrated and intensified cognitive behaviour therapy for treating social anxiety disorder (SAD). The aim of this study was to examine the feasibility of the Bergen 4-Day Treatment (B4DT) for treating SAD.

METHODS:

This study adopted an open trial design without a control group. Thirty consecutively referred patients who were diagnosed with SAD were treated and assessed at pre-treatment, at post-treatment, and at the 3-month follow-up. The Liebowitz Social Anxiety Scale was used to assess symptoms of SAD; the Generalized Anxiety Disorder-7 scale was used to assess anxiety symptoms; and the Patient Health Questionnaire-9 was used to assess symptoms of anxiety and depression. The Client Satisfaction Questionnaire-8 was administered posttreatment.

RESULTS:

Overall, patients reported a high level of satisfaction with the B4DT. Large effect sizes were observed for symptoms of SAD (d = 1.94-2.66) and for the secondary outcomes, i.e., generalized anxiety (d = 0.86-0.99) and depression (d = 0.62-0.83). The remission rate was 55.2% at follow-up, while the treatment response rate was 89.7%.

CONCLUSIONS:

The B4DT is a promising treatment approach for patients with SAD. In the future, controlled trials should be performed to compare the efficacy of this treatment approach with standard outpatient treatment. Practical consequences, policy implications, and suggestions for future research are discussed herein.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fobia Social Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fobia Social Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article